CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells.
Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
eEF-2K在应激反应和细胞代谢中具有重要作用。我们在此报告eEF-2K在调控CD8+ T细胞命运和杀细胞活性中一个此前未被充分认识但至关重要的角色。来自eEF-2K KO小鼠的CD8+ T细胞在激活后比野生型 counterparts 更具增殖性,但存活率更低,随后出现早衰和耗竭。eEF-2K KO CD8+ T细胞代谢更活跃,并表现出Akt-mTOR-S6K通路的过度激活。eEF-2K的缺失显著损害了CD8+ T细胞的活性。此外,与对照CAR-CD8+ T细胞相比,缺乏eEF-2K的CAR-CD8+ T细胞的抗肿瘤疗效和肿瘤浸润显著降低。因此,eEF-2K对于维持细胞毒性CD8+ T细胞的活力和功能至关重要,治疗性增强该激酶可能被开发为一种增强CAR-T 抗肿瘤治疗的新方法。
eEF-2K has important roles in stress responses and cellular metabolism.
We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8 + T cells. CD8 + T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8 + T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8 + T cells.
Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8 + T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8 + T cells.
Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8 + T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。